The NIH Office of Technology Transfer has now made it easier for companies to find inventions to license by using the iPhone app. This app provides real-time streaming of information and provides easy searching for technologies available for licensing. Information is provided on technologies developed at NIH and FDA available for further R&D and potential commercialization. In addition, technologies that require further collaboration through the CRADA mechanism are also included in the feed.
The app shows a teaser of the available technologies, full access to the description on the website, enables the user to contact the NIH Office of Technology Transfer directly via phone, email, or on the website, enables the user to share technologies on Twitter or Facebook, and enables the user to email links directly to the technologies.
NCI has a software system with applications available for licensing that has applications for clinical prognosis, personalized medicine, and for clinical research. The system can provide prognostic information for different diseases and in particular for cancer. The software can determine whether a particular genotype has a significant association with survival time for an individual receiving treatment. For example, it can determine if a specific genetic pattern is associated with an increased or decreased time for a recurrence of a particular type of cancer for patients on a given treatment regimen.
NCI is interested in parties available to do further collaborative research and to develop, evaluate, or commercialize the technology described above. For further information, contact John Hewes, PhD, at 301-435-3121 or email email@example.com.
FDA is seeking a device company to commercialize its patent pending hand-held portable device based on Light Emitting Diodes (LED) as a light source to use to detect counterfeit pharmaceutical drugs and packaging.
Current methods for detecting counterfeit pharmaceuticals although generally effective require expensive and bulky instrumentation and generally needs to be done in a laboratory with highly trained operators. This new device is small in size, light, portable, easy to use, cost is low, and simple to manufacture.
The device (Ref.No 2165) is fully developed, ready for manufacturing, and available for licensing. For more information, email Michael Shmilovich at firstname.lastname@example.org or call 301-402-0220.
RapiDx, is a prototype portable diagnostic instrument, based on lab-on-a-chip technologies.
The device is designed to rapidly measure toxins and disease biomarkers in human biological samples with high sensitivity for application in point-of-care clinical diagnostics.
Sandia National Laboratories, the first commercial partner on the system plans to license the background intellectual property related to RapiDx to AM Biotechnologies, so the company can manufacture commercial devices in their field. In addition, Sandia is in discussion with several businesses that are interested in marketing the system for specific market applications.
Another technology of interest is Sandia’s “ElectroNeedle”™ Biomedical Sensor Array. This is a device that when pressed against the skin, provides rapid on-demand multiplexed, point-of-care biomedical assays for medical diagnosis. The device is able to provide rapid on-demand diagnostics especially critical in emergencies, on the battlefield, and in remote settings where time constraints or distance make it impractical to send the patient’s samples to a conventional laboratory for analysis.
A new biotechnology company New Mexico Biotech, Inc. has been formed in Albuquerque explicitly for “ElectroNeedle”™ commercialization. The company has licensed the technology from Sandia and plans to develop the commercial product, pursue FDA approval, and provide funding to Sandia for continued R &D.